Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Martinez

Physician Assistant San Antonio, TX Physician Assistant

NPI 1497179998 CMS profile 10668992

520 E Euclid Ave, San Antonio, TX 78212

Open in the dashboard

General payments

$13,557

738 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Martinez of San Antonio, TX is reported in the CMS Open Payments database as having received $13,557 across 738 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,996 212
2024 General $3,021 163
2023 General $3,259 179
2022 General $1,622 86
2021 General $1,660 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Martinez
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jennifer Martinez were reported at $3,996. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jennifer Martinez Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,660 $132 $37–$438 $132
2022 $1,622 $155 $48–$522 $149
2023 $3,259 $167 $52–$557 $160
2024 $3,021 $178 $55–$600 $164
2025 $3,996 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,324 195 payments
  2. Janssen Biotech, Inc. $1,653 84 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,122 83 payments
  4. Lilly USA, LLC $717 26 payments
  5. Ipsen Biopharmaceuticals, Inc $709 49 payments
  6. Pfizer Inc. $709 40 payments
  7. QOL Medical, LLC $494 22 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $471 28 payments
  9. Celgene Corporation $444 30 payments
  10. Aimmune Therapeutics, Inc. $416 22 payments
  11. Other $3,500 159 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,169 728 payments
  2. Education $388 10 payments
Products named General payments · program years 2021–2025
  1. MAVYRET $1,449 85 payments
  2. STELARA $1,109 49 payments
  3. XIFAXAN $891 66 payments
  4. TREMFYA $771 38 payments
  5. IQIRVO $648 43 payments
  6. OMVOH $641 23 payments
  7. RINVOQ $608 31 payments
  8. ZENPEP $603 36 payments
  9. XELJANZ $578 33 payments
  10. LINZESS $511 32 payments
  11. Other $7,009 376 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

363

Median for Physician Assistant: 241

Drug cost

$91,147

Median for Physician Assistant: $4,110

Branded share of claims

23.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Viberzi Eluxadoline Brand 16 $35,543
Linzess Linaclotide Brand 26 $30,380
Motegrity Prucalopride Succinate Brand 15 $10,591
Sucralfate Generic 35 $6,567
Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 13 $1,751
Colestipol Hcl Generic 15 $1,525
Omeprazole Generic 78 $1,385
Ondansetron Odt Ondansetron Brand 16 $873
Pantoprazole Sodium Generic 41 $779
Famotidine Generic 36 $773

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$29,353

Medicare's payments for the services billed

Medicare patients

289

Average age 72

Services billed

443

172 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 45%
Ischemic heart disease 34%
Chronic kidney disease 32%
Depression 26%
Heart failure 17%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MAVYRET
  • AbbVie, Inc. $398
$398 — —
STELARA
  • Janssen Biotech, Inc. $179
  • Janssen Scientific Affairs, LLC $110
$288 — —
OMVOH
  • Lilly USA, LLC $277
$277 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $204
$204 — —
TREMFYA
  • Janssen Biotech, Inc. $154
  • Janssen Scientific Affairs, LLC $18
$172 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

738 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record